The GOLGA3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, serving as a loss-of-function model for the Golgi structural protein golgin-160 (GOLGA3). This polyclonal knockout population facilitates the study of GOLGA3 in Golgi ribbon maintenance, vesicular trafficking, and apoptosis signaling without clonal bias.
A-549 cells, isolated from a 58-year-old male lung adenocarcinoma, are a widely used model for non-small cell lung cancer (NSCLC) with alveolar basal epithelial characteristics. They are employed extensively to investigate oncogenic signaling, drug response, and apoptotic pathways, providing a relevant background for examining GOLGA3??s role in cancer cell biology.
GOLGA3 (golgin-160) is a Golgi resident protein critical for maintaining Golgi ribbon structure and mediating vesicle transport. Upon apoptotic stimuli, it is cleaved by caspase-3 and caspase-7, leading to Golgi fragmentation and amplification of apoptosis signaling. It interacts with GOLGA2 (GM130) and GORASP1 (GRASP65), and its cleavage disrupts these complexes. GOLGA3 functions downstream of caspase activation and upstream of Golgi disassembly, altered secretion, and impaired apoptosis. Pathway components include GOLGA2, GORASP1, CASP3, Rab GTPases, and COPI/COPII coats, highlighting its role in Golgi organization and transport.
In A-549 cells, GOLGA3 knockout enables investigation of the interplay between Golgi integrity and cancer cell survival. GOLGA3 is implicated in apoptosis resistance through caspase-mediated cleavage, linking organelle disassembly to apoptotic amplification. In NSCLC, dysregulated apoptosis is a hallmark of progression and therapy resistance. Additionally, autoantibodies to golgins like GOLGA3 are found in autoimmunity, extending this model??s relevance to golgin autoimmunity research. Disrupting GOLGA3 allows assessment of Golgi fragmentation effects on secretion and drug sensitivity.
Researchers can use these cells for immunofluorescence microscopy with markers like GM130, western blotting for GOLGA3 and cleaved fragments, apoptosis assays (Annexin V, caspase-3 activation), cell viability assays, and secretion assays (e.g., luciferase secretion). The polyclonal nature supports population-level studies, suitable for high-content screening or pooled functional genomics. For technical inquiries, please contact Ascent Research.
